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Malignant Glioblastoma Cells 
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1University of Salerno, Department of Pharmacy, Italy 
2University of Edinburgh, MRC Centre for Inflammation Research, UK 
Abstract: Glioblastoma multiforme (GBM) is the most common malignant and resistant tumor of the central nervous sys-
tem in humans and new therapeutic strategies are urgently required. Recently, we have shown that the potential chemo-
therapeutic polyphenol xanthohumol (XH), isolated from Humulus Lupulus, induces apoptosis of human T98G glioblas-
toma cells by increasing reactive oxygen species and activating MAPK pathways. Then we have found, by western blot-
ting and microscopic analysis, that XH up-regulates cytosolic levels of ANXA1 and induces translocation of the protein 
on the cell membrane of T98G cells in a time-dependent manner with significant effects observed after 24 h. On the basis 
of the above evidence, the aim of this work was to investigate the role of intracellular and cell membrane localized 
ANXA1 in GBM cells. RT-PCR analysis has shown that XH up-regulates mRNA levels of ANXA1 after 16 h treatment. 
To demonstrate the involvement of ANXA1 in apoptosis of GBM cells we down-regulated ANXA1 expression with small 
interfering RNA (siRNA) and then analysed apoptosis in the presence and absence of apoptotic stimuli. Importantly, 
apoptosis induced by XH was reduced in siRNA-ANXA1 transfected cells where western blot analysis shows a significant 
reduction of ANXA1 protein levels. To investigate the role of ANXA1 expression on the cell membrane of T98G cells as 
potential “eat-me” signal we studied phagocytosis of apoptotic cells by human macrophages. We incubated apoptotic 
T98G cells with human blood monocyte derived macrophages (M=). After co-incubation period we analysed the percent-
age of M= phagocytosing the apoptotic cells by cytofluorimetric FACS analysis and by confocal microscopy. Our results 
show that XH induces phagocytosis of apoptotic T98G cells by human M= in a concentration-effect manner, a processes 
that is dependent on caspase mediated apoptosis. ANXA1 acts as an “eat-me” signal on the cell membrane of T98G cells, 
and interestingly, apoptotic siRNA-ANXA1 transfected cells are not completely ingested by M=. These results were con-
firmed by incubating apoptotic cells with a neutralizing anti-ANXA1 antiboby and ANXA1 membrane depletion by 
EDTA washing. ANXA1 was also detected in supernatants of apoptotic cells and the incubation of enriched supernatants 
enhanced the percentage of phagocytosis by M=. These results demonstrated that ANXA1 is involved both in the apop-
tosis and phagocytosis of glioblastoma cells. This study shows a possible role of ANXA1 in maintenance of brain homeo-
stasis and may lead to novel therapeutic approaches for neuro-inflammatory diseases and chemotherapy targets in the 
treatment of glioblastoma multiforme. 
Keywords: Annexin, Glioblastoma multiforme, polyphenols. 
INTRODUCTION 
 GBM (WHO grade IV) is the most common tumor of the 
central nervous system (CNS) in humans and is particularly 
highly aggressive and invasive exhibiting rapid cell growth, 
resistance to apoptosis and robust angiogenesis. Unfortu-
nately, the median survival of GMB patients is 6-12 months 
from the time of diagnosis and current treatments, including 
surgery, radiation therapy and chemotherapy have not sig-
nificantly improved the prognosis [1]. The major limitations 
of chemotherapy for the treatment of GBM are the inability 
of many drugs to pass through the blood-brain barrier and 
their low efficacy to induce apoptosis. Therefore the choice 
of effective drugs is limited and new therapeutic strategies  
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urgently need to be explored. There is increasing evidence 
that several natural compounds found in plants may be useful 
as cancer chemopreventive or chemotherapeutic agents. Xan-
thohumol (XH) is one of the major prenylated phenolics oc-
curring in the hop cones of Humulus lupulus L.. Hops are 
traditionally used to add bitterness and flavor to beer, how-
ever, more recently alternative uses for hop polyphenols and 
their effect on several biological processes have become ap-
parent. Limited in vitro studies indicate that several preny-
lated flavonoids present in the hop plant possess anticancer 
properties. In particular, XH has received major attention be-
cause it has been shown to inhibit initiation, promotion and 
progression stages of carcinogenesis, hence appearing as a 
broad-spectrum chemopreventive agent [2]. Anticancer ac-
tivities of several beer polyphenols, including XH, have been 
investigated in various cell lines. For example, XH inhibits 
human breast (MCF-7), colon (HT-29), ovarian (A2780), 
prostate (DU145, PC-3) cancer [3] and B-chronic lympho-
cytic leukemia cell proliferation [4] and induces apoptosis in 
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human breast [5] and prostate cancer cells in vitro [6]. In ad-
dition, pro-apoptotic effects of a hop-bitter acid, humulone 
(H), in the leukemia cell lines, HL60 and U937, have also 
been reported [7]. A recent in vivo study showed the ability 
of xanthohumol to induce a significant inhibition of angio-
genesis in mice implanted with a matrigel sponge when ad-
ministered in the drinking water at a concentration of 2M. 
At higher concentration of 200 M XH displayed a marked 
angiogenesis inhibition without adverse effect on animal 
health parameters [8]. It has also been shown that XH targets 
tumor growth and angiogenesis in Kaposi’s sarcoma tumor 
in male nude mice [9]. 
 ROS, such as superoxide anion (O2.-), hydrogen peroxide 
(H2O2) and hydroxyl radical (HO.) influence many biological 
processes, including apoptosis [10]. The redox state of the 
cells is a crucial factor in deciding its susceptibility to apop-
totic stimuli [11]. ROS at low concentrations play a role as 
intracellular messengers regulating several processes includ-
ing cell proliferation, while the production of large amounts 
of ROS promote apoptosis [12]. Flavonoids are generally 
considered to be antioxidants, but most of them behave as 
powerful pro-oxidant molecules [13-15]. XH is structurally 
related to flavonoids and although may exert antioxidant ac-
tivity, it also appears to increase the cellular content of ROS 
[16]. It has been found that XH-induced apoptosis in leuke-
mic K562 cells was associated with elevation of cellular 
ROS content and that the antioxidant N-acetylcysteine 
(NAC) blunted XH induced apoptosis [17]. 
 Flavonoids can also trigger apoptosis through modulation 
of different signal transduction pathways, such as the phos-
phatidyinositol-3-kinase/Akt and mitogen activated protein 
kinase (MAPK) pathways, which may affect cellular func-
tion by modulating genes regulation or phosphorylating pro-
teins [18]. Furthermore, they can directly or indirectly affect 
the activity and expression of key proteins (e.g., caspases, 
Bcl-2 family members) involved in the regulation of apop-
tosis, It has been found that XH-induced apoptosis in K562 
cells was associated with a prolonged stimulation of ERK 
phosphorylation [19]. Moreover, recently it has been re-
ported that certain flavonoids induce apoptosis in human 
glioblastoma T98G and U87MG cells, but not in human 
normal astrocytes through increase of ROS production, 
changes in mitochondria membrane potential (m) and 
phosphorylation of MAPKs [20].  
 Recently, we have shown that the potential chemothera-
peutic polyphenol xanthohumol (XH), isolated from Humu-
lus Lupulus, induces apoptosis of human T98G glioblastoma 
cells by increasing reactive oxygen species and activating 
MAPK pathways [21]. Then we have found, by western blot-
ting and microscopic analysis, that XH up-regulates cytoso-
lic levels of ANXA1 and induces translocation of the protein 
on the cell membrane of T98G cells in a time-dependent 
manner with significant effects observed after 24 h. On the 
basis of the above evidence, the aim of this work was to in-
vestigate the role of intracellular and cell membrane local-
ized ANXA1 in GBM cells. RT-PCR analysis has shown 
that XH up-regulates mRNA levels of ANXA1 after 16 h 
treatment. To demonstrate the involvement of ANXA1 in 
apoptosis of GBM cells we down-regulated ANXA1 expres-
sion with small interfering RNA (siRNA) and then analysed 
apoptosis in the presence and absence of apoptotic stimuli. 
MATERIALS AND METHODS 
Cell Cultures 
 Human glioblastoma T98G (WHO grade IV) and U87-
MG (WHO grade III) cell lines, obtained from ATCC, were 
cultured in DMEM medium supplemented with 2 mM L-
glutamine, 10% heat-inactivated fetal bovine serum (FBS), 
1% sodium pyruvate, 1% non-essential amino acids and 1% 
penicillin/streptomycin (all from Lonza, Switzerland) at 
37°C in 5% CO2 humidified incubator. The cells were used 
up to a maximum of 10 passages. 
Western Blot Analysis 
 Expression of ANXA1 on cell surface and cytosolic level 
was evaluated by Western blot analysis. For cell surface pro-
teins, cells, kept on ice, were washed with PBS containing 
protease and phosphatase inhibitors (1mM PMSF, 10 µg/ml 
leupeptin, 10 µg/ml pepstatin, 10 µg/ml aprotinin, 1 mM 
Na3VO4, 1 mM NaF; Sigma-Aldrich, Milan, Italy) and 5 
mM EDTA (Sigma-Aldrich, Milan, Italy), which acts as a 
Ca2+ chelating agent, removing the ANXA1 bound to the 
cell membrane. The intracellular proteins were extracted 
from cells by a lysis buffer (50 mM Tris-HCl, 1% Na-
deoxycholate, 1% SDS and 0.5% IGEPAL) containing pro-
tease and phosphatase inhibitors (1mM PMSF, 10 µg/ml le-
upeptin, 10 µg/ml pepstatin, 10 µg/ml aprotinin, 1 mM 
Na3VO4, 1 mM NaF; all supplied by Sigma-Aldrich, Milan, 
Italy). 
 The lysed cells were then centrifuged at 12,000 xg at 4°C 
for 10 min. The supernatant is the extract of proteins. Protein 
content was estimated according to Biorad protein assay 
(BIO-RAD, Milan, Italy). Protein samples (30 µg) were 
loaded onto 10% acrylamide gel and separated by SDS-
PAGE. The separated proteins were then transferred electro-
phoretically (100 mA Blot for 90 minutes; Trans Blot semi-
dry, Biorad) to nitrocellulose membrane (Immobilon-NC, 
Millipore, Bedford, USA), using a transfer buffer [25mM 
Tris, 192 mM glycine (Sigma-Aldrich, Milan, Italy) and 20% 
v/v methanol (Carlo Erba, Milan, Italy)]. The non-specific 
binding were blocked by incubation of membrane in TBS-
TWEEN 0.1% (25 mM Tris; 150 mM NaCl, 0.1% v/v 
Tween) with 5% nonfat dry milk (BIO-RAD, Milan, Italy) in 
for 60 minutes. Subsequently, the membranes were incu-
bated overnight at 4°C with primary antibodies: anti-rabbit 
polyclonal ANXA1 (Invitrogen) and anti-β-actin monoclonal 
93 mouse (Sigma-Aldrich, Italy). After incubation with pri-
mary antibodies and 3 washes in TBS-Tween 0.1%, were 
added specific secondary anti-rabbit or anti-mouse, diluted 
1:5000, (both supplied by Sigma-Aldrich, Milan, Italy) for 1 
hour at room temperature. The specific signals were visual-
ized by chemiluminescence detection system (GE Health-
care, Milan, Italy). Digital im
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scribed by Riccardi and Nicoletti (2006). Briefly, cells were 
washed in phosphate-buffered saline (PBS) and resuspended 
in 500 µl of a solution containing 0.1% sodium citrate, 0.1% 
Triton X-100 and 50 µg/ml propidium iodide (Sigma-
Aldrich, Milan, Italy). After incubation at 4C° for 30 minutes 
in the dark, cell nuclei were analyzed with Becton Dickinson 
FACScan flow cytometer using the Cells Quest program. 
Cellular debris was excluded from analysis by raising the 
forward scatter threshold, and the DNA content of the nuclei 
was registered on logarithmic scale. The percentage of the 
cells in the hypodiploid region was calculated. 
Transfection with Small-interference RNA (siRNA) Anti-
ANXA1 
 Two small interference RNAs (siRNA) were designed for 
ANXA1: ANXA1 (A) (sense 5'-CAGCGUCAACAGAU-
CAAAG-3') and ANXA1 (B) (sense 5'-CCGAUCUGAG-
GACUUUGGU-3' (Dharmacon Research Inc., Lafayette, 
CO, USA). The scrambled siRNA oligo-KROAA OO6461 
(sense 5'-CAGUCGCGUUUGCGACUGG-3') (Dharmacon 
Research Inc., Lafayette, CO, USA) was used as control. 
1.5x105 cells were plated in 6-well multiwell plate reaching a 
confluence of 30-50% and kept in DMEM containing 10% 
FBS. The transfection was performed using oligofectamine 
(Invitrogen, Milan, Italy) according to manufacturer’s in-
structions, and obtaining a final mixture of RNA (A) and (B) 
100nM. After 48 hours, the cells are treated in the presence 
and in the absence of XH (20 μM) and analyzed by flow cy-
tometry and western blot. 
Real-time RT-PCR Analysis 
 Total RNA was isolated from T98G cells using TRIzol 
Reagent (Invitrogen, Carlsbad, CA, USA) according to 
manufacturer’s instructions. The RNA quality was assessed 
by agarose gel electrophoresis. The RNA quantity was 
measured using a spectrophotometer. Three micrograms of 
isolated RNA were reverse-transcribed using oligo(dT) 
primer and SuperScriptII (Invitrogen, Carlsbad, CA, USA) in 
a total volume of 20 μl. Real-time PCR was performed with 
Light-Cycler® System Ver. 3.5 (Roche Diagnostics GmbH, 
Mannheim, Germany) using SYBR Green detection in a total 
volume of 20 µl with 1 µl of forward and reverse primers (10 
mM) and 10 µl of SYBR GreenPCRMaster-Mix (Roche Di-
agnostics GmbH, Mannheim, Germany). Reactions included 
an initial cycle at 95°C for 10 min, followed by 40 cycles of 
denaturation at 95°C for 10 sec, annealing at 55°C for 5 sec, 
extension at 72°C for 15 sec. Values were determined from 
standard curve generated from serial cDNA dilutions and 
normalized to GAPDH. Fold change of induction were de-
termined by calculating ratios between control and treatment 
normalized signals. Differences between mean values were 
evaluated for statistical significance using the unpaired Stu-
dent t-test. (Differences were considered significant with 
P<0.05.) Primers used for real-time PCR are as follows: 
ANXA1 forward 5’-ATCAGCGGTGAGCCCCTATC -3’ 
and reverse 5’- TTCATCCAGGGGCTTTCCTG -3’, 
GAPDH forward 5’- AATTCCATGGCACCGTCAAGG -3’ 
and reverse 5’- TCGCCCCACTTGATTTTGGAG -3’. 
 
CONFOCAL MICROSCOPY 
 T98G cells were seeded on 12mm slides with their cul-
ture medium and after 24 hours were treated with xanthohu-
mol 20 µM for 24 hours. After incubation time the culture 
medium was removed and cells in adhesion on glass slides 
were washed twice with PBS. Subsequently, the cells were 
fixed with para-formaldehyde at 3.7% for 20 minutes and 
then washed with PBS. Then it was added a 0.1M glycine 
solution and incubated for 5 minutes. After washing with 
PBS, the cells were incubated with 1% BSA in PBS for 1 
hour. The cells were then incubated with the primary anti-
body polyclonal anti-ANXA1 (1:100) (Zymed, Invitrogen) 
for 2 hours. Cells were also incubated with DAPI (4,6-
diamidin-2-phenylindole) (1:1000) to obtain a staining of 
cell nuclei. Subsequently the cells were washed 2 times with 
PBS and incubated with the secondary antibody Alexa Fluor 
647 anti-rabbit for 30 minutes. After 2 more washes with 
PBS the slides were mounted on the door slides with Moviol 
(3-4μl/vetrino). The slides were kept in cells down until the 
reading performed with Leica confocal microscope and ob-
served with a 63X magnification. 
Activity Assay of Caspase-3 
 The activity of caspase-3 in cellular extracts was deter-
mined analyzing the release of 7-amino-4-methylcoumarin 
(AMC) from N-acetyl-DEVD-AMC (Nicholson, 1995). The 
cells (2x106) were lysed in a buffer containing 10 mM Tris-
HCl, 10 mM NaH2PO4/NaHPO4 (pH 7.5), 130 mM NaCl, 
1% Triton -X-100, 10 mM NaPPi (sodium pyrophosphate). 
20μg of protein were incubated with 20 μM Ac-DEVD-
AMC (Becton Dickson) in the reaction buffer [ 20 mM 
HEPES (pH 7.5), 10% glycerol and 2 mM dithiothreitol 
(DTT)] at 37°C for 2 hours. AMC release is monitored in a 
spectrofluorometer at an excitation wavelength of 380 nm 
and an emission wavelength range of 430-460 nm (L55 Lu-
minescence Spectometrer, Perkin Elmer Instruments). 
STATISTICAL ANALYSIS 
 All results are mean ± SEM of 3 experiments performed 
in triplicate. The optical density of the protein bands detected 
by Western blotting was normalized on β-actin levels. Statis-
tical comparison between groups were made using Bon-
ferroni parametric test. Differences were considered signifi-
cant if p < 0.05. 
RESULTS 
Effects of Xanthohumol on the Induction of Apoptosis in 
Different Cell Lines of Glioblastoma 
 In the first phase of this work, we evaluated the apoptosis 
induced by xanthohumol in different glioblastoma cell lines 
with different degrees of malignancy the T98G (WHO IV), 
the U87-MG (WHO III-IV) and U343-MG (WHO III). It 
was therefore verified the effect on apoptosis of 
xanthohumol, at various concentrations and at different 
times, in different lines of glioblastoma with a different 
degree of malignancy. The cells were incubated for 8, 24 and 
48 hours in the presence and in the absence of xanthohumol  
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to different concentrations 10, 20, 50 μM. At the end of the 
incubation periods of all three cell lines were harvested to 
assess apoptosis by measuring the percent of hypodiploid 
cells by flow cytometry. The data reported in Fig. (1A) show 
that the effects of xanthohumol induces apoptosis in T98G 
cells already at 24 hours with an effect massimoa 48 hours 
after treatment at a concentration of 20 uM. Fig. (1B and C) 
shows the effects of xanthohumol in different concentrations 
and at different times on the other two cell lines, the U-87 
and U-343 with a lower degree of malignancy. Xanthohumol 
is capable of inducing a small effect on apoptosis of U87MG 
cells only at the highest concentration at 48 h (p <0.05 vs. 
CTR) while in U343MG cells, xanthohumol gives no 
significant effect to the times and at the concentrations used. 
These results revealed that the T98G cells are much more 
sensitive U87-MG and U343-MG to the action of 
xanthohumol. Based on this result we have chosen the use of 
XH 20 uM concentration as the optimal treatment conditions 
in T98G cells of glioblastoma multiforme. 
Effects of the Xanthohumol on the Total Expression of 
ANXA1 in Various Cell Lines of Glioblastoma 
 To verify a possible modulation of the expression of 
ANXA1 by xanthohumol, the three different cell lines of 
glioblastoma (T98G, U87-MG and U343-MG) were 
incubated in the presence or absence of xanthohumol 
(20μM) at the times indicated in graph. After obtaining the 
total cellular protein extracts, 35μg of protein were analyzed 
by Western blotting using polyclonal anti-ANXA1. The 
immunoreactive protein bands were detected by 
chemiluminescence and quantized by densitometric analysis, 
normalizing the levels of the protein on the expression of 
actin obtained in the same extracts. Fig. (2) shows that the 
effect of xanthohumol on the modulation of the expression of 
ANXA1 is found only in T98G cells, in fact there is no 
change in the levels of expression of ANXA1 nor in U87-
MG cells nor in U343-MG cells. Fig. (2) shows that the 
effect of xanthohumol in T98G on the expression of ANXA1 
is time-dependent. Xanthohumol induces a significant 
increase in protein levels at 16 hours after stimulation, with a 
maximum peak of expression at 48 hours. 
Effects of Xanthohumol on the Expression of ANXA1 in 
the Cytosol and Plasma Membrane in T98G Cells 
 On the basis of interesting preliminary data obtained 
about apoptosis and the expression of ANXA1 following 
treatment with xanthohumol, in different cell lines of 
glioblastoma, we decided to study the role of ANXA1 in 
apoptosis induced by XH in cells of glioblastoma multiforme 
T98G where the expression of protein by the XH was posi-
tively regulated. So we have assessed the possible modula-
tion of expression of ANXA1 by xanthohumol in the cytosol 
 
Fig. (1). Dose/effect curve at different administration time of three different cell lines of glioblastoma (A) T98G, (B) U87-MG and (C) 
U343-MG. Apoptosis was induced by xanthohumol at different concentrations (10-20-50μM) after administration at different times (8-24-48 
hours) and measured by flow cytometry, as a percentage of hypodiploid nuclei by permeabilization and incorporation of iodide of propridio 
(PI). Data are shown as mean ± SEM of three experiments performed in triplicate. (A) ° P <0.05, ° ° P <0.01 vs CTR T98G cells 24 h, * P 
<0.05, ** P <0.01, *** P <0.001 vs CTR T98G cells 48h. (B) * P <0.05 vs. CTR cells U87-MG 48 h. 
20
0
0 8 24 48
A
(hrs)
40
60
80
CTR
%
 a
po
pt
ot
ic
 c
el
ls
(h
yp
od
lp
lo
ld
 n
uc
el
)
%
 a
po
pt
ot
ic
 c
el
ls
(h
yp
od
lp
lo
ld
 n
uc
el
)
%
 a
po
pt
ot
ic
 c
el
ls
(h
yp
od
lp
lo
ld
 n
uc
el
)
***
***
*
*
oo
o
XH 10 μM
XH 20 μM
XH 50 μM
T98G
20
0
0 8 24 48
B
(hrs)
40
60
80
20
0
0 8 24 48 (hrs)
40
60
80
CTR
XH 10 μM
XH 20 μM
XH 50 μM
U87-MG
CCTRXH 10 μM
XH 20 μM
XH 50 μM
U343
The Involvement of Xanthohumol in the Expression of Annexin in Human The Open Biochemistry Journal, 2013, Volume 7    5 
and on the membrane of T98G cells. The cells were plated at 
a density of 5x106 cells / ml and incubated in the presence 
and in the absence of xanthohumol (20 μM) at the times in-
dicated by Fig. (3A). After obtaining the extracts cytosolic, 
30 μg of protein were analyzed by Western blotting using a 
polyclonal antibody directed against ANXA1. The immuno-
reactive protein bands were highlighted by means of 
chemiluminescence. The Western, in Fig. (3A) shows that 
the effect of xanthohumol on the expression of cytosolic 
ANXA1 is time-dependent. Xanthohumol induces a signifi-
cant increase of the protein, with a peak expression at 48 
hours. For the extraction of membrane proteins after the 
treatment times, the cells were incubated on ice with a solu-
tion of 5 mM EDTA PBS that acts as a chelating agent of 
Ca2+ and removes the ANXA1 anchored to the cell mem-
brane via the Ca2+. Subsequently 10 µg for membrane pro-
teins were analyzed by Western blotting, using a polyclonal 
anti-ANXA1. The Western, in Fig. (3B), shows that the ex-
pression of ANXA1 on the membrane surface increases al-
ready at 16 hours after stimulation with a peak expression at 
48 hours. Xanthohumol is capable of promoting the translo-
cation and thus the exposure of the protein on the membrane 
of T98G cells. To confirm the data obtained by Western blot-
ting, the expression of ANXA1 on the membrane, following 
treatment with 20μM XH, has been evaluated through fluo-
rescence microscopy performed with a confocal microscope 
(Leica) using a 63X magnification. The cells were plated on 
12 mm slides and kept in culture for 24 hours before per-
forming the treatments with XH. At the end of the incubation 
period the cells were washed and incubated with the primary 
antibody and polyclonal anti-ANXA1 contemporanemanete 
were also incubated with DAPI (4,6-diamidin-2-
phenylindole) to obtain a staining of cell nuclei. The red 
color in the image of Fig. (3C) shows an accumulation of 
ANXA1 on the cell membrane as a result of treatment with 
xanthohumol to 24 hours thus confirming the data obtained 
previously by western blotting. 
 
Fig. (2). Effects of xanthohumol on the expression of ANXA1 in 
three different glioblastoma T986, U87-MG and 4343-MG.cell 
lines: The three cell lines were incubated in the presence and in the 
absence of xanthohumol 20μM at different time points (0-48 h). 
The expression of ANXA1 was analyzed by Western blotting, 
using a polyclonal anti-ANXA1 and normalizing the amount of 
protein analyzed by an antibody anti-β-actin. 
Effects of Xanthohumol on the Transcriptional Regula-
tion of ANXA1 
 Based on the results obtained previously, we wanted to 
investigate the effects of xanthohumol at the transcriptional 
level thus assessing the levels of mRNA for ANXA1. After 
treating the cells with 20μM xanthohumol at different times 
(8, 16, 24), we performed a real-time PCR. The amplifica-
tions and RT-PCR analysis were performed on a Light-
cycler system (Roche) using the kit Light Cycler Fast Start 
DNA Master plus SYBR Green I (Roche Molecular Bioche-
micals, Mannheim, Germany). ANXA1 and the GADPH 
gene were amplified with specific primers and then the 
mRNA levels of ANXA1 were normalized with those of 
GADPH. The analysis results show, as seen in Fig. (4), 
which XH induces an increase in mRNA levels for ANXA1 
in a time-dependent manner with a peak at 24 hours thus 
confirming a transcriptional regulation of the protein by 
xanthohumol. 
Effects of siRNA Directed Against ANXA1 on the Ex-
pression of ANXA1 in T98G Cells in the Presence and 
Absence of Xanthohumol 
 To evaluate the involvement of xanthohumol in the up-
regulation of ANXA1 mRNA levels in T98G cells, we used 
small interference RNA directed against ANXA1 to down-
 
Fig. (3). Effects of xanthohumol on the expression of ANXA1 in 
the cytosol and on the membrane of human T98G glioblastoma 
multiforme cells. (A) Analysis of the expression of ANXA1 in the 
cytosol of T98G cells. (B) Expression of levels of ANXA1 on the 
plasma membrane of cells T98G. T98G cells were incubated in the 
presence or absence of xanthohumol (20μM) at different times. The 
expression of ANXA1 was analyzed by Western blotting using a 
polyclonal anti-ANXA1. (C) Expression of levels of ANXA1 on 
the plasma membrane of T98G cells analyzed by confocal 
fluorescence microscopy. After 24 hours of incubation the cells 
were treated with 20μM xanthohumol for the stated time, 
subsequently the cells were washed and incubated with a polyclonal 
antibody anti-ANXA1 and with DAPI to have a colored of the 
nuclei. The intense red color that is seen in the figure is indicative 
of the presence of ANXA1 on the membrane. 
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regulate its expression. T98G cells, plated in multi-well 6-
well, were transfected in the presence of oligofectamina 
containing a mixture of two siRNA directed against ANXA1 
and simultaneously with siRNA-Scrambled used as a con-
trol. The cells were incubated with siRNAs for 48 hours and 
subsequently treated with xanthohumol (20μM). The protein 
extracts (30μg) were analyzed by means of Western blotting 
using a polyclonal anti-ANXA1 and an anti - actin for 
standardization. In control cells xanthohumol significantly 
increases the expression of ANXA1. The small interference 
directed against ANXA1 significantly inhibit the expression 
of ANXA1 both in the presence and absence of xanthohu-
mol. The cells with siRNAs-scrambled present ANXA1 
levels comparable to those of the control cells as evidenced 
by densitometric analysis shown in the graph (Fig. 5). The 
siRNAs directed against ANXA1 are able to significantly 
inhibit the expression of the protein both in the presence and 
absence of xanthohumol, in T98G cells. 
Effects of siRNA Directed Against ANXA1 Apoptosis In-
duced by Xanthohumol in T98G Cells 
 To further analyze the effects of small interference 
directed against ANXA1 on apoptosis induced by 
xanthohumol, T98G cells were cultured with or without 
siRNA or siRNA-Scrambled-ANXA1. After 48 hours of 
transfection, the cells were treated with or without XH 
(20μM) and harvested after 48 hours to evaluate the percent 
of hypodiploid nuclei by flow cytometry. The data obtained 
show that, in cells transfected with scrambled siRNA 
induced apoptosis xanthohumol is almost unchanged 
compared to the cells not transfected and treated with 
xanthohumol. However in T98G cells transfected with 
siRNAs directed against ANXA1 apoptosis induced by 
xanthohumol is partially, but significantly inhibited (Fig. 
6A). Then we also evaluated the activity of caspase-3 after 
transfection with siRNA-ANXA1 in T98G cells. The cells 
were transfected with and without siRNA-ANXA1 and 
 
Fig. (4). Effect of xanthohumol on ANXA1 mRNA expression. Fold change of induction were determined by calculating ratio between 
control and treatment normalized signals. Data are means ± SD of three independent experiments. * P≤0.01. 
 
Fig. (5). Effects of siRNAs directed against ANXA1 expression da togliere in T98G cells. T98G cells were transfected with oligofectamina 
containing concentrations of 100nM of small interference oligonucleotides directed against ANXA1 and scrambled control. After 48 hours of 
transfection, the cells were treated with xanthohumol 20μ for 24 h. Subsequently 30μg of protein were analyzed by Western blotting using a 
polyclonal antibody anti ANXA1. Data are shown as optical density, mean ± SEM of three representative experiments. Bonferroni test (*** 
P <0.001 vs CTR, ° ° ° P <0.001 vs scrambled xanthohumol and xanthohumol +). 
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siRNA-Scrambled and after 48 hours of incubation were 
treated with xanthohumol (20μM) for 8, 24 and 48 hours. 
After the incubation period with xanthohumol cells were 
used to measure the activity of caspase-3 by fluorimetric 
assay according to the method reported in the section 
materials and methods. The results obtained in Fig. (6B) 
show that the activity of caspase-3 has decreased 
significantly in cells transfected with siRNA-ANXA1 after 
24-48 hours from treatment with xanthohumol compared to 
treatment with xanthohumol in cells not transfected with and 
xanthohumol in cells transfected with siRNA-Scrambled 
control. These data demonstrate that in the absence of 
ANXA1, the apoptosis induced by xanthohumol is signifi-
cantly reduced confirming the involvement del'ANXA1 in 
the activation of caspase-3 and in the mechanism of cell 
death induced by xanthohumol. 
DISCUSSION  
 Glioblastoma multiforme is one of the most common 
cancers and malignant brain. The median survival for 
patients with GBM is 12.6 months from diagnosis for 
patients treated surgically and those treated with 
radiotherapy or chemotherapy. The prognosis of GBM is 
very poor, relative survival for adult patients diagnosed with 
GBM is 25% at one year, 5% in three years, 3% at five 
years, with no difference between men and women. The 
treatment of choice feasible in the case of GBM is definitely 
surgery and removal should be as radical as possible, even if 
in reality it is a highly invasive tumor complete resection is 
impossible and relapse is almost inevitable. Surgical therapy 
along with that radiotherapy and chemotherapy is part of 
palliative therapy that, though with modest results, allows to 
increase the duration of life of the patient. The drug most 
widely used for the treatment of GBM is temozolomide 
which is often used in combination with other 
chemotherapeutic agents to prevent the progression of the 
tumor. It is based on the lack of effective chemotherapeutic 
agents for the treatment of this tumor that arises the need 
always to search for new therapeutic valid strategies. In 
recent years, the natural products have been the focus of 
numerous studies, in order to find agents with potent 
antitumor activity. Some phenolic constituents extracted 
from hop cones have been shown to have a potential action 
for the prevention and treatment of various cancers. 
 Among the various components of the hops, 
xanthohumol, a chalcone prenilato of Humulus lupulus L., it 
was found a good chemopreventive and chemotherapeutic 
agent in many experimental models, both in vitro and in 
vivo, and has been shown to have a pro-apoptotic in T98G 
glioblastoma multiforme cells. In fact in a previous study, 
 
Fig. (6). (A) Effect of siRNA-ANXA1 on apoptosis of T98G cells analyzed by staining with propidium iodide (PI) as an expression of 
hypodiploid nuclei. The cells were transfected for 48 hours with siRNA-ANXA1 (100nM) and siRNA-scrambled (SK) control and 
subsequently treated with xanthohumol for 24 hours. (B) Effect of siRNA-ANXA1 activation of caspase-3 in T98G cells measured by 
fluorimetric assay. The cells were transfected for 48 hours with si-RNA-ANXA1 (100nM) and subsequently treated with xanthohumol for 8-
24-48 hours and then analyzed by fluorometric assay specific for caspase-3. Data are shown as mean  ± SEM of three representative 
experiments representative. Bonferroni test (*** P <0.001 vs. control cells; § § § P <0.001 vs. control cells and cells transfected with SK, ° ° 
P <0.01 vs. cells treated with XH and XH + SK). 
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conducted in our laboratory, it has been demonstrated that 
apoptosis induced by XH is associated with the activation of 
caspase-3, caspase-9 and the cleavage of PARP, and is 
mediated by signaling pathway intrinsic mitochondrial and 
amplified by depolarization of the mitochondrial membrane, 
by the release of cytochrome c from the negative regulation 
of anti-apoptotic protein Bcl-2. It was also demonstrated that 
XH induces the release of intracellular ROS. The intracellar 
production of ROS is essential for the activation of the 
signaling pathway mitochondrial and the induction of 
apoptosis after exposure to XH. Oxidative stress caused by 
the treatment with the XH was also associated with 
activation of MAPK, as shown by the increase in the 
phosphorylation of ERK1 / 2 and p38. Xanthohumol is not 
able to induce cell death in primary cultures of cells 
astroticiche not transformant thus indicating a selectivity of 
action towards cancer cells of glioblastoma multiforme. 
 The ANXA1, initially characterized as a cytosolic protein 
with anti-inflammatory activity induced by glucocorticoids, 
over the past few years has shown to be present also at the 
level of the membrane and to be involved in various 
biological mechanisms phones as well as pathological, such 
as cancer. Of great interest in recent times is the study of the 
biological activities of ANXA1 including the inflammatory 
process, cell proliferation, the adjustment of the signals of 
cell death, apoptosis, and as demonstrated for the first time 
from an article by McKanna [22] , the phagocytic removal of 
apoptotic cells. It is known that the ANXA1 has an anti-
inflammatory action due also to the stimulation of the release 
of anti-inflammatory cytokines [23]. It is therefore 
conceivable that the ANXA1 exposed on the cell membrane 
represents an anti-inflammatory signal and contributes to the 
removal of apoptotic cells without triggering an 
inflammatory response. Alterations in the expression of 
ANXA1, increase or decrease, were observed in a wide 
variety of tumors. Numerous studies conducted over the past 
decade have revealed an important role dall'ANXA1 in the 
process of apoptosis and as recognition signal "Eat-me" 
("Eat") expressed on the membrane of apoptotic cells [24] .  
 In this work has been shown that the ANXA1 is a ligand 
of engulfment transported from the cytosol to the membrane 
where colocalizes with phosphatidylserine during the final 
stage of clarification of the apoptotic process. On the basis of 
these premises, the aim of this work was to study the role of 
ANXA1 in apoptosis induced by xanthohumol in human 
glioblastoma cells 
 In the first phase of this work, we evaluated the apoptosis 
induced by xanthohumol in different glioblastoma cell lines 
with different degrees of malignancy: the T98G (WHO IV), 
the U87-MG (WHO III-IV) and U343-MG (WHO III) cells . 
The apoptosis was evaluated after treating cells with xantho-
humol at different concentrations and different times. The 
results obtained show that the effects of xanthohumol on 
apoptosis in T98G cells are already detectable at 24 hours 
with a maximum effect at 48 hours after treatment at a con-
centration of 20 uM. Furthermore xanthohumol is capable of 
inducing a small effect on apoptosis of U87MG cells only at 
the highest concentration at 48 h, whereas in cells U343MG 
gives no significant effect to the times and at the concentra-
tions used. These data reveal a specific selective action be-
cause the cells of high-grade malignancy T98G cells are 
much more sensitive U87-MG and U343-MG cells action of 
xanthohumol. On the basis of these results was chosen as the 
optimal concentration for use of xanthohumol that of 20 uM. 
To assess a possible modulation of ANXA1 induced by xan-
thohumol in the three lines we used the technique of Western 
blotting and evaluated the expression of the protein at differ-
ent times. The data obtained show that xanthohumol induces 
increased expression of ANXA1 only in T98G cells, in fact 
there is no change in the levels of expression of ANXA1 nor 
in U87-MG nor in U343-MG cells. The effect of xanthohu-
mol in T98G on the expression of ANXA1 is time-
dependent. Xanthohumol induces a significant increase in 
levels of the protein at 16 hours after stimulation, with a 
maximum peak of expression at 48 hours. A better under-
standing of the expression and function of ANXA1 in tumor 
biology may lead to the identification of new markers of tu-
mor progression and potential targets for therapeutic inter-
vention. To example, the expression of ANXA1 is little pre-
sent in undifferentiated tumors with a high degree of malig-
nancy [25]. 
 Based on preliminary data obtained about apoptosis and 
the expression of ANXA1 following treatment with xantho-
humol, in different glioblastoma cell lines, the next step was 
to investigate the role of ANXA1 in apoptosis induced by 
XH in cells glioblastoma T98G where the expression of pro-
tein by the XH was up-regulated. So we have assessed the 
possible modulation of ANXA1 expression by xanthohumol 
in the cytosol and on the membrane of cells T98G by West-
ern blotting technique. The data obtained reveal that the ef-
fect of xanthohumol on the ANXA1 expression in the cyto-
sol is time-dependent. Xanthohumol induces an increase of 
the protein, with a peak expression at 48 hours. Furthermore 
XH is capable of regulating the expression of ANXA1 also 
on the surface of the cell membrane which increases already 
at 16 hours after stimulation with a maximum peak of ex-
pression at 48 hours. Xanthohumol is then able to promote 
translocation and thus the exposure of ANXA1 on the mem-
brane of cells T98G. These data have been confirmed by the 
analysis of confocal fluorescence microscopy which shows a 
highly significant accumulation of ANXA1 on the cell mem-
brane as a result of treatment with XH at 24 hours compared 
to control cells where the expression in membrane was 
hardly visible. The ANXA1 exposed on the membrane of 
T98G cells induces to hypothesize a possible role of the pro-
tein as signal "eat me" on apoptotic cells and therefore an 
important role in facilitating the elimination of apoptotic 
cells by macrophages without producing phenomena of in-
flammatory type. Our current studies are evaluating the role 
of ANXA1 exposed on the membrane of T98G cells in 
phagocytosis by macrophage cells human. The study of these 
mechanisms will clarify the role of the protein in the ex-
tracellular level and can open new developments for the 
study of drugs that target ANXA1 in the mechanisms that 
facilitate the removal of tumor cells without activating proc-
esses of inflammatory type. The presence of annexin A1 is 
also important to maintain homeostasis of the brain and was 
also found in microglia where McArthur et al. [26] have 
suggested that he was involved in the removal of apoptotic 
neurons in both inflammatory and non-inflammatory condi-
tions. 
 The next step was to investigate the effects of 
xanthohumol of ANXA1 at the transcriptional level thus 
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assessing the levels of mRNA for ANXA1. The results of the 
analysis obtained by RT-PCR shows that XH induces an 
increase in mRNA levels for ANXA1 in a time-dependent 
with a peak at 24 hours thus confirming that XH regulates 
transcriptional expression of the protein. The promoter 
dell'ANXA1, in fact, has an AP1 site which can be 
stimulated by phorbol esters and induce the expression of the 
protein [27]. It is also known that xanthohumol is capable of 
stimulating the region of the AP-1 promoter ANXA1 thus 
inducing an increase in the levels of interleukin-2 in T cells 
[28] At this point to verify the real involvement of ANXA1 
in apoptosis induced by XH, in T98G cells, we performed 
transfection using a small interference RNA directed against 
ANXA1 to silence the expression of the protein. Following 
48 hours of incubation with the siRNAs and following 
treatment with xanthohumol, the protein extracts were 
analyzed by western blotting technique. In control cells 
xanthohumol significantly increases the expression of 
ANXA1. The cells transfected with siRNAs-scrambled 
present ANXA1 levels comparable to those of the control 
cells while in those transfected with siRNAs directed against 
ANXA1 protein expression was inhibited significantly both 
in the presence and absence of xanthohumol. Last phase of 
this paper was to examine whether the levels of ANXA1 
could affect the xanthohumol-induced apoptosis in T98G 
cells. To do this we employed the small interference directed 
against ANXA1 for the expression, scrambled siRNA 
control and subsequently evaluated apoptosis induced by 
xanthohumol. 
 The data obtained show that, in cells transfected with 
control siRNA induced apoptosis xanthohumol is almost 
unchanged compared to the cells not transfected and treated 
with xanthohumol, whereas in cells transfected with siRNAs 
anti ANXA1 where the expression of ANXA1 was 
significantly inhibited the 'apoptosis induced by 
xanthohumol resulted partially, but significantly inhibited. 
To confirm the role of ANXA1 in the mechanism of 
apoptosis we also assessed the activity of caspase-3 after 
transfection with siRNA-ANXA1 in T98G cells using 
fluorimetric assay. The results show that the activity of 
caspase-3 has decreased significantly in cells transfected 
with siRNA-ANXA1 after 24-48 hours from treatment with 
xanthohumol compared to treatment with xanthohumol in 
cells not transfected with xanthohumol and in cells 
transfected with siRNA-scrambled control. These data 
demonstrate that in the absence of ANXA1, the apoptosis 
induced by xanthohumol is significantly reduced confirming 
the involvement del'ANXA1 in the activation of caspase-3 
and in the mechanism of cell death induced by xanthohumol. 
CONCLUSION 
 The results obtained in this work show that: 
- Xanthohumol induces apoptosis in T98G glioblastoma 
multiforme cell lines with a high degree of malignancy. 
These cells prove to be very sensitive to its action, and do 
not see any significant effect in other lines of glioblastoma to 
malignancy grade below which the U87MG and U343MG 
cells. 
- Xanthohumol positively regulates the expression of 
ANXA1 in T98G cells with a mechanism of transcriptional 
type (Fig. 7) 
- Xanthohumol induces the translocation of ANXA1 from 
the cytosol to the cell membrane positively adjusting the 
exposure on the membrane of T98G cells late in the final 
stage of apoptosis. ANXA1 could then be a signal of 
phagocytosis to facilitate the removal of dead cells by 
macrophages. 
- ANXA1 is partially involved in the mechanisms of 
apoptosis induced by xanthohumol of T98G cells by 
regulating the activity of the protease caspase-3.  
- Further studies on the mechanisms mediated by ANXA1 
in glioblastoma multiforme may be important for the 
 
Fig. (7). Xanthohumol positively regulates the expression of ANXA1 in T98G cells with a mechanism of transcriptional type. 
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development of new drugs that regulate the apoptotic process 
in these malignant disease 
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